MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

A

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

Search

Twist Bioscience Corp

Closed

SectorHealthcare

42.5 0.47

Overview

Share price change

24h

Current

Min

41.62

Max

43.09

Key metrics

By Trading Economics

Income

-48M

-27M

Sales

3M

99M

Profit margin

-27.41

Employees

979

EBITDA

3.2M

-21M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+0.14% upside

Dividends

By Dow Jones

Next Earnings

2 Feb 2026

Market Stats

By TradingEconomics

Market Cap

669M

2.5B

Previous open

42.03

Previous close

42.5

News Sentiment

By Acuity

50%

50%

148 / 352 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

27 Jan 2026, 23:07 UTC

Earnings

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27 Jan 2026, 21:27 UTC

Earnings

Texas Instruments 4Q Sales Rise, Profit Falls

27 Jan 2026, 23:55 UTC

Market Talk

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27 Jan 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 Jan 2026, 23:47 UTC

Market Talk

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27 Jan 2026, 23:39 UTC

Market Talk

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27 Jan 2026, 23:20 UTC

Earnings

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27 Jan 2026, 23:20 UTC

Earnings

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27 Jan 2026, 23:19 UTC

Earnings

SK Innovation Posts Net Loss for Second Consecutive Year

27 Jan 2026, 23:19 UTC

Earnings

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27 Jan 2026, 23:18 UTC

Earnings

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27 Jan 2026, 23:18 UTC

Earnings

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27 Jan 2026, 23:11 UTC

Market Talk

Global Equities Roundup: Market Talk

27 Jan 2026, 23:11 UTC

Market Talk

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27 Jan 2026, 23:07 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27 Jan 2026, 22:17 UTC

Market Talk

U.S. Dollar Slips Following Trump Comments -- Market Talk

27 Jan 2026, 22:06 UTC

Earnings

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27 Jan 2026, 21:51 UTC

Earnings

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27 Jan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 Jan 2026, 21:43 UTC

Earnings

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27 Jan 2026, 21:41 UTC

Earnings

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27 Jan 2026, 21:38 UTC

Earnings

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27 Jan 2026, 21:32 UTC

Earnings

Ampol: Modest Profit From F&I International in 2025

27 Jan 2026, 21:32 UTC

Earnings

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27 Jan 2026, 21:31 UTC

Earnings

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27 Jan 2026, 21:31 UTC

Earnings

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27 Jan 2026, 21:30 UTC

Earnings

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27 Jan 2026, 21:29 UTC

Earnings

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27 Jan 2026, 21:29 UTC

Earnings

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27 Jan 2026, 21:28 UTC

Earnings

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

0.14% upside

12 Months Forecast

Average 43 USD  0.14%

High 50 USD

Low 39 USD

Based on 6 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

148 / 352 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat